Zymeworks Inc. Share Price
NASDAQ: ZYME | Small CapZymeworks Inc. Stock Performance
Open $23.78 | Prev. Close $23.23 | Circuit Range N/A |
Day Range $23.50 - $24.18 | Year Range $11.54 - $29.72 | Volume 30,242 |
Average Traded $23.78 |
Zymeworks Inc. Share Price Today
As of 10 August 2026, Zymeworks Inc.'s share price is $23.52. The stock opened at $23.78, compared to its previous close of $23.23. During today's trading session, Zymeworks Inc.'s share price traded between $23.50 and $24.18, with an average price of $23.84. Over the past 52 weeks, the stock has recorded a high of $29.72 and a low of $11.54. In terms of performance, Zymeworks Inc.'s share price has risen by 0.79% over the last six months and is up 58.89% on a year-on-year basis.
Zymeworks Inc. Share Price Chart
Zymeworks Inc. Stock Fundamentals & Key Indicators
Market Cap $1.77B | PE Ratio (TTM) -21.77 | Dividend Yield N/A |
EPS (TTM) $-1.08 | Revenue (TTM) $105.97M | Return On Equity (TTM) -30.22% |
Profit Margin -76.56% | Debt to Equity 0.16 | Quarterly Earnings Growth YoY 34.33% |
Zymeworks Inc. Quarterly Profit & Loss
All figures in USD
Zymeworks Inc. Annual Profit & Loss
All figures in USD
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Zymeworks Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $22.02 | $23.52 | +7.10% |
Jul 2026 | $26.18 | $21.96 | -16.45% |
Jun 2026 | $24.84 | $26.29 | +4.66% |
May 2026 | $26.97 | $25.11 | -8.92% |
Apr 2026 | $25.04 | $27.57 | +10.17% |
Mar 2026 | $22.91 | $25.03 | +7.29% |
Feb 2026 | $22.70 | $23.33 | +3.46% |
Jan 2026 | $26.04 | $22.55 | -14.39% |
Dec 2025 | $26.29 | $26.34 | -1.50% |
Nov 2025 | $18.99 | $26.74 | +40.07% |
Oct 2025 | $17.02 | $19.09 | +11.77% |
Sep 2025 | $14.49 | $17.08 | +15.41% |
ZYME Share Price FAQs
What is Zymeworks Inc. share price today?
What is the 52 week high and 52 week low of Zymeworks Inc. stock?
What is ZYME's market capitalisation today?
What is ZYME's net income for the last quarter?
What is the 5 year returns of ZYME?
What is the high & low stock price of ZYME today?
Can I buy ZYME shares in India?